Impact of financial incentives on the value of the marginal drug

From an interesting review paper in the Journal of Economic Perspectives by Craig Garthwaite: Although research and development investments clearly respond to market opportunities, the exact benefits created by these incremental investments remain unclear. This is largely because the exact marginal products developed in response to these incentives are elusive to identify. Certainly, the amount…

Read More

Novavax Sees Sanofi Vaccine Pact as Model for Future Deals, Some Going Beyond Infectious Disease

Novavax’s partnership with Sanofi allows the pharma giant to explore potential combinations of assets from both companies, and it’s a blueprint for the kinds of alliances the vaccine developer is pursuing. Rather than commercializing vaccines, Novavax aims to turn its research into business development deals, R&D executive Ruxandra Draghia-Akli said. The post Novavax Sees Sanofi…

Read More

Different Data Source, But Same Results: Most Adults Subject to Medicaid Work Requirements Are Working or Face Barriers to Work

To understand the impact of Medicaid work requirements included in the budget reconciliation bill being debated in Congress, KFF has undertaken two difference analyses using different data sources. Using 2023 data from the Survey of Income and Program Participation, this analysis looks at the share of adults who work at least 80 hours per month,…

Read More